Wadenberg M L, Hertel P, Fernholm R, Hygge Blakeman K, Ahlenius S, Svensson T H
Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden.
J Neural Transm (Vienna). 2000;107(10):1229-38. doi: 10.1007/s007020070036.
Blockade of central alpha1-adrenoceptors has been implicated as a possible factor contributing to the atypical antipsychotic profile of clozapine. Thus, in the present study we examined the effects of concomitant alpha1-adrenoceptor and dopamine D2 receptor blockade on conditioned avoidance response performance, as an index of antipsychotic-like activity, and on the induction of catalepsy, as a test for extrapyramidal side effect liability, in rats. It was found that pretreatment with the alpha1-adrenoceptor antagonist prazosin (0.2mg kg(-1) s.c.) caused an enhancement of a suppression of conditioned avoidance response in the presence of the dopamine D2 receptor antagonist raclopride (0.05-0.20 mg kg(-1) s.c.). The effect was most prominent at a subthreshold dose of raclopride (0.05 mg kg(-1)). At these doses, prazosin or raclopride by themselves, or in combination, did not produce catalepsy. In addition, pretreatment with prazosin (0.2mgkg(-1) s.c.) did not alter the catalepsy produced by a higher dose of raclopride (1.0 mg kg(-1) s.c.). It is suggested that, in the presence of low dopamine D2 receptor occupancy, additional alpha1-adrenoceptor blockade might improve antipsychotic efficacy, and thereby improve the therapeutic window with regard to parkinsonism.
中枢α1-肾上腺素能受体的阻断被认为可能是氯氮平非典型抗精神病药特性的一个促成因素。因此,在本研究中,我们研究了同时阻断α1-肾上腺素能受体和多巴胺D2受体对条件性回避反应表现(作为抗精神病样活性指标)以及对僵住症诱导(作为锥体外系副作用倾向测试)在大鼠中的影响。结果发现,在多巴胺D2受体拮抗剂雷氯必利(0.05 - 0.20mg/kg皮下注射)存在的情况下,用α1-肾上腺素能受体拮抗剂哌唑嗪(0.2mg/kg皮下注射)预处理可增强对条件性回避反应的抑制。在雷氯必利阈下剂量(0.05mg/kg)时,这种作用最为显著。在这些剂量下,单独使用哌唑嗪或雷氯必利,或两者联合使用,均未产生僵住症。此外,用哌唑嗪(0.2mg/kg皮下注射)预处理并未改变较高剂量雷氯必利(1.0mg/kg皮下注射)所产生的僵住症。这表明,在多巴胺D2受体占有率较低的情况下,额外阻断α1-肾上腺素能受体可能会提高抗精神病疗效,从而改善帕金森症方面的治疗窗口。